Empagliflozin
First drug to treat ‘full spectrum’ of chronic heart failure approved by UK regulator: Empagliflozin is the only licensed treatment for adults with symptomatic chronic heart failure with preserved or reduced ejection fraction Bracknell, UK, 14 June 2022 – The UK medicines regulator has approved empagliflozin as a treatment for adults with symptomatic chronic heart […]